[go: up one dir, main page]

WO2002009793A8 - Dispositif de traitement de maladies du systeme immunitaire - Google Patents

Dispositif de traitement de maladies du systeme immunitaire

Info

Publication number
WO2002009793A8
WO2002009793A8 PCT/DE2001/002884 DE0102884W WO0209793A8 WO 2002009793 A8 WO2002009793 A8 WO 2002009793A8 DE 0102884 W DE0102884 W DE 0102884W WO 0209793 A8 WO0209793 A8 WO 0209793A8
Authority
WO
WIPO (PCT)
Prior art keywords
support
immune diseases
blood
treating immune
human body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2001/002884
Other languages
German (de)
English (en)
Other versions
WO2002009793A1 (fr
Inventor
Torsten Matthias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeskulab Diagnostika
AESKU LAB DIAGNOSTIKA
Original Assignee
Aeskulab Diagnostika
AESKU LAB DIAGNOSTIKA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeskulab Diagnostika, AESKU LAB DIAGNOSTIKA filed Critical Aeskulab Diagnostika
Priority to DE10193004T priority Critical patent/DE10193004D2/de
Priority to AU2001278407A priority patent/AU2001278407A1/en
Publication of WO2002009793A1 publication Critical patent/WO2002009793A1/fr
Publication of WO2002009793A8 publication Critical patent/WO2002009793A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0415—Plasma
    • A61M2202/0417—Immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un dispositif de traitement de maladies du système immunitaire comprenant un conduit d'alimentation destiné au sang et/ou aux constituants sanguins aqueux et pouvant être raccordé à un point de prélèvement du sang placé dans un organisme humain, un conduit de dérivation pouvant être raccordé à un point de renvoi du sang placé dans l'organisme humain et un support situé entre le conduit d'alimentation et le conduit de dérivation et présentant une surface. Le dispositif est caractérisé en ce que la surface du support présente des antigènes immobilisés qui lient de façon sélective des immunglobulines agressives. Les antigènes immobilisés qui, de préférence, ne sont pas présents dans le sérum, sont liés au support notamment à l'aide d'une fixation par liaison non covalente.
PCT/DE2001/002884 2000-07-27 2001-07-27 Dispositif de traitement de maladies du systeme immunitaire Ceased WO2002009793A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10193004T DE10193004D2 (de) 2000-07-27 2001-07-27 Vorrichtung zur Behandlung von Immunerkrankungen
AU2001278407A AU2001278407A1 (en) 2000-07-27 2001-07-27 Device for treating immune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10036742A DE10036742A1 (de) 2000-07-27 2000-07-27 Vorrichtung zur Behandlung von Immunerkrankungen
DE10036742.9 2000-07-27

Publications (2)

Publication Number Publication Date
WO2002009793A1 WO2002009793A1 (fr) 2002-02-07
WO2002009793A8 true WO2002009793A8 (fr) 2002-04-18

Family

ID=7650487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/002884 Ceased WO2002009793A1 (fr) 2000-07-27 2001-07-27 Dispositif de traitement de maladies du systeme immunitaire

Country Status (3)

Country Link
AU (1) AU2001278407A1 (fr)
DE (2) DE10036742A1 (fr)
WO (1) WO2002009793A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842746A1 (fr) * 2002-07-26 2004-01-30 Univ Nancy 1 Henri Poincare Colonne d'immunoaffinite pour epuration d'anticorps comportant des microparticules polymeres encapsulant des antigenes associes a des phospholipides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103184B1 (fr) * 1982-08-12 1990-01-17 Kanegafuchi Chemical Industry Co., Ltd. Activation de terpolymères biocompatibles par des agents biologiques dont les compléments à fixer sont des effecteurs pathologiques
DE3664729D1 (en) * 1985-04-09 1989-09-07 Terumo Corp Immunoglobulin adsorbent and adsorption apparatus
US4865841A (en) * 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
WO1989004675A1 (fr) * 1987-11-20 1989-06-01 Creative Biomolecules, Inc. Elimination selective de complexes immuns
EP0661980B1 (fr) * 1991-08-23 2003-02-19 Alberta Research Council Procedes et compositions d'attenuation de rejet de xenogrephe induit par les anticorps chez les receveurs humains
DE19538641C2 (de) * 1995-10-05 2000-09-21 Privates Inst Bioserv Gmbh Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
PT1049499E (pt) * 1998-01-20 2004-03-31 Mitra Medical Technology Ab Aparelho para uso na extraccao de elementos especialmente anticorpos exogenos presentes no sangue ou no plasma
AU2408700A (en) * 1999-01-11 2000-08-01 Baxter International Inc. Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma

Also Published As

Publication number Publication date
WO2002009793A1 (fr) 2002-02-07
AU2001278407A1 (en) 2002-02-13
DE10036742A1 (de) 2002-02-21
DE10193004D2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
CA2429027A1 (fr) Anticorps contre le recepteur humain h4-1bb
WO2002090566A3 (fr) Anticorps recombine a specificite tumorale et utilisation correspondante
WO2002096948A3 (fr) Anticorps tetravalents modifies et procedes d'utilisation
WO2003072736A3 (fr) Reactifs et methodes therapeutiques de maladies auto-immunes
WO2003043583A3 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
WO2003068201A3 (fr) Anticorps presentant une specifite de type recepteur des lymphocytes t, une affinite encore superieure, et utilisation de celui-ci dans la detection et le traitement du cancer, d'infections virales et de maladies auto-immunes
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2003030835A3 (fr) Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
WO2003016467A3 (fr) Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
WO2003037911A3 (fr) Anticorps permettant d'inhiber la coagulation sanguine et procedes d'utilisation associes
WO2007022520A3 (fr) Renfort induit par anticorps de reponse immune
WO2003026692A3 (fr) Traitement de l'inflammation articulaire chronique
AU2001288342A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2006021955A3 (fr) Utilisation d'anticorps monoclonaux bat pour l'immunotherapie
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
WO2003004049A3 (fr) Agent therapeutique
HUP0200484A2 (en) Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
WO2001040473A3 (fr) Antigenes de pseudomonas aeruginosa
MXPA02009449A (es) Ligandos dirigidos a la region no del eje del componente no secretor de la pigr y metodos de uso de los mismos.
WO2002009793A8 (fr) Dispositif de traitement de maladies du systeme immunitaire
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP